MedTrace Logo

A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation

NCT00511771 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2010-11-18

No results posted yet for this study

Summary

To provide tegaserod to eligible women adult patients who did not have satisfactory improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) symptoms with other available treatment(s) and / or patients who had satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC.

Conditions

  • Irritable Bowel Syndrome With Constipation
  • Chronic Idiopathic Constipation

Interventions

DRUG

Tegaserod

Tegaserod maleate

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
54 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00511771 on ClinicalTrials.gov